WaveMan
WaveMan · Company
NTRA · Natera, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NTRA Natera (NTRA) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001604821
Quote by TradingView
Form 144 · 23
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
517
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $771.6K priced

What the filings say about NTRA

Insiders, 180 days
-$182.8M net sold
11 sellers · 36% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2025-09-22
Planned sales (Form 144), 90 days
$110.4M
23 notices

Natera insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Natera, Inc. insiders sold a net $182.8M of stock across 1,431 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Sheena Jonathan
Director
SELL
2026-10-23 SECtraded 2026-10-21
200
$81.3K
n/a
Context
  • 410 earlier Form 4 trades (code P or S) here by this insider (410 sales), the last on Oct 16, 2026.
  • The trade is 0.1% of the 221,114 shares held after it.
  • 3 other insiders sold within 30 days.
  • 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheena Jonathan sold about $81.3K of NTRA under a 10b5-1 plan on Oct 21, 2026; 3 other insiders sold within 30 days and 517 funds added in the latest 13F quarter.
Sheena Jonathan
Director
SELL
2026-10-23 SECtraded 2026-10-21
962
$392.7K
n/a
Context
  • 410 earlier Form 4 trades (code P or S) here by this insider (410 sales), the last on Oct 16, 2026.
  • The trade is 0.4% of the 220,152 shares held after it.
  • 3 other insiders sold within 30 days.
  • 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheena Jonathan sold about $392.7K of NTRA under a 10b5-1 plan on Oct 21, 2026; 3 other insiders sold within 30 days and 517 funds added in the latest 13F quarter.
Sheena Jonathan
Director
SELL
2026-10-23 SECtraded 2026-10-21
627
$257.0K
n/a
Context
  • 410 earlier Form 4 trades (code P or S) here by this insider (410 sales), the last on Oct 16, 2026.
  • The trade is 0.3% of the 219,525 shares held after it.
  • 3 other insiders sold within 30 days.
  • 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheena Jonathan sold about $257.0K of NTRA under a 10b5-1 plan on Oct 21, 2026; 3 other insiders sold within 30 days and 517 funds added in the latest 13F quarter.
Sheena Jonathan
Director
SELL
2026-10-23 SECtraded 2026-10-21
605
$248.8K
n/a
Context
  • 410 earlier Form 4 trades (code P or S) here by this insider (410 sales), the last on Oct 16, 2026.
  • The trade is 0.3% of the 218,920 shares held after it.
  • 3 other insiders sold within 30 days.
  • 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheena Jonathan sold about $248.8K of NTRA under a 10b5-1 plan on Oct 21, 2026; 3 other insiders sold within 30 days and 517 funds added in the latest 13F quarter.
Sheena Jonathan
Director
SELL
2026-10-23 SECtraded 2026-10-21
211
$87.0K
n/a
Context
  • 410 earlier Form 4 trades (code P or S) here by this insider (410 sales), the last on Oct 16, 2026.
  • The trade is 0.1% of the 218,709 shares held after it.
  • 3 other insiders sold within 30 days.
  • 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheena Jonathan sold about $87.0K of NTRA under a 10b5-1 plan on Oct 21, 2026; 3 other insiders sold within 30 days and 517 funds added in the latest 13F quarter.
1,431 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1,426 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$182.8M over 180 days
-$102.1M over 90 days
below 89% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
517 funds bought in last quarter
more than 97% of Healthcare Services
Revenue
+35.9% year over year
more than 84% of Healthcare Services
Margin
-9.0% net margin
below 71% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
more than 59% of Healthcare Services
What changed in the last 30 days
Oct 23Director Sheena Jonathan sold $1.9M under a 10b5-1 plan (20 trades, Oct 16 to Oct 21)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 21Director Sheena Jonathan filed to sell $3.9M by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 16EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $20.1M under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Director MATTHEW RABINOWITZ filed to sell $19.7M by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer SOLOMON MOSHKEVICH filed to sell $1.2M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch NTRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+114.8%12M
-3%+40%+83%+126%2025-102025-122026-022026-042026-062026-082026-10 2025-11-03 · Chapman Steven Leonard sold $31.3M2026-01-20 · Chapman Steven Leonard sold $16.9M2026-02-02 · Chapman Steven Leonard sold $9.6M2026-01-21 · Brophy Michael Burkes sold $8.9M2026-09-11 · Rabinowitz Matthew sold $5.9M2026-06-01 · BOTHA ROELOF sold $5.8M2026-01-20 · Brophy Michael Burkes sold $5.6M2026-01-20 · Moshkevich Solomon sold $5.4M2026-09-11 · Rabinowitz Matthew sold $5.2M2026-09-15 · Rabinowitz Matthew sold $5.1M2025-12-12 · ROSENMAN HERM sold $5.0M2026-09-02 · Moshkevich Solomon sold $5.0M2026-03-16 · Rabinowitz Matthew sold $4.9M2026-06-01 · BOTHA ROELOF sold $4.7M2026-02-02 · Chapman Steven Leonard sold $4.6M2026-01-20 · RABINOWITZ DANIEL sold $4.5M2025-11-24 · BOTHA ROELOF sold $4.5M2026-03-12 · Rabinowitz Matthew sold $4.2M2026-01-20 · Fesko John sold $4.2M2026-10-15 · Rabinowitz Matthew sold $4.2M2026-06-24 · ROSENMAN HERM sold $4.1M2026-03-13 · Rabinowitz Matthew sold $4.1M2026-06-24 · RABINOWITZ DANIEL sold $4.1M2026-03-13 · Rabinowitz Matthew sold $4.0M2025-11-24 · BOTHA ROELOF sold $3.6M2026-09-11 · Rabinowitz Matthew sold $3.5M2025-11-04 · Rabinowitz Matthew sold $3.4M2025-11-03 · Rabinowitz Matthew sold $3.4M2026-06-01 · BOTHA ROELOF sold $3.3M2025-12-12 · ROSENMAN HERM sold $3.3M2026-03-16 · Rabinowitz Matthew sold $3.2M2026-03-13 · Rabinowitz Matthew sold $3.2M2026-09-14 · Rabinowitz Matthew sold $2.8M2026-09-15 · Rabinowitz Matthew sold $2.8M2026-06-24 · RABINOWITZ DANIEL sold $2.8M2025-12-12 · ROSENMAN HERM sold $2.7M2026-03-13 · Rabinowitz Matthew sold $2.6M2026-06-12 · Rabinowitz Matthew sold $2.6M2026-06-15 · Rabinowitz Matthew sold $2.6M2026-10-15 · Rabinowitz Matthew sold $2.5M2026-10-15 · Rabinowitz Matthew sold $2.5M2026-10-15 · Rabinowitz Matthew sold $2.4M2026-10-21 · Sheena Jonathan filed to sell $3.9M2026-10-15 · MATTHEW RABINOWITZ filed to sell $19.7M2026-10-01 · STEVEN L CHAPMAN filed to sell $526.1K2026-10-01 · SOLOMON MOSHKEVICH filed to sell $1.2M2026-09-23 · Sheena Jonathan filed to sell $8.2M2026-09-15 · TINKERBELLE II TR U/A DTD 10/22/2021 filed to sell $700.0K2026-09-11 · MATTHEW RABINOWITZ filed to sell $65.2M2026-09-02 · SOLOMON MOSHKEVICH filed to sell $02026-09-01 · STEVEN L CHAPMAN filed to sell $545.0K2026-09-01 · SOLOMON MOSHKEVICH filed to sell $962.2K2026-08-07 · Sheena Jonathan filed to sell $6.0M2026-08-07 · TINKERBELLE II TR U/A DTD 10/22/2021 filed to sell $641.8K2026-08-04 · MICHAEL BROPHY filed to sell $129.2K2026-08-03 · MICHAEL BROPHY filed to sell $83.8K2026-08-03 · STEVEN CHAPMAN filed to sell $312.5K2026-08-03 · STEVEN L CHAPMAN filed to sell $502.7K2026-08-03 · JOHN FESKO filed to sell $78.2K2026-08-03 · SOLOMON MOSHKEVICH filed to sell $795.8K2026-08-03 · SOLOMON MOSHKEVICH filed to sell $108.4K2026-08-03 · MATTHEW RABINOWITZ filed to sell $193.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NTRA: institutional holders (13F)

13F holdings, latest reported quarter
JPMORGAN CHASE & CO
12,865,346 sh
$3.5B
BlackRock, Inc.
10,914,608 sh
$3.0B
VANGUARD CAPITAL MANAGEMENT LLC
6,228,216 sh
$1.7B
VANGUARD PORTFOLIO MANAGEMENT LLC
5,782,640 sh
$1.6B
FMR LLC
5,451,396 sh
$1.5B

Congress trades in NTRA

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Josh Gottheimer
Bought 2025-09-22 · disclosed 23 days later
$1,001 - $15,000
Josh Gottheimer
Bought 2025-08-22 · disclosed 14 days later
$1,001 - $15,000
Josh Gottheimer
Sold 2025-07-22 · disclosed 20 days later
$1,001 - $15,000
Josh Gottheimer
Bought 2024-11-20 · disclosed 15 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NTRA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Sheena Jonathan
Filed 2026-10-21
$3.9M
MATTHEW RABINOWITZ
Filed 2026-10-15
$19.7M
STEVEN L CHAPMAN
Filed 2026-10-01
$526.1K
SOLOMON MOSHKEVICH
Filed 2026-10-01
$1.2M
Sheena Jonathan
Filed 2026-09-23
$8.2M

NTRA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Genomic Advancements ETF
$2.1M position · as of 2026-06-30
7.5%
Paradigm Select Fund
$16.1M position · as of 2026-06-30
5.7%
TrueShares Technology, AI & Deep Learning ETF
$2.3M position · as of 2026-06-30
5.5%
VanEck Biotech ETF
$19.5M position · as of 2026-06-30
4.9%
Sterling Capital Special Opportunities Fund
$16.5M position · as of 2026-06-30
4.7%
Catalyst Insider Buying Fund
$970.4K position · as of 2026-06-30
4.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Natera, Inc. Pac (Natera Pac)
Cycle 2026 · $69K spent
$95.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$15.0M
$60.8M
$6.8M
+130%
+25%
2024
$13.0M
$95.4M
$6.1M
+59%
-7%
2023
$12.7M
$32.8M
$4.9M
-37%
-6%
2022
$8.2M
-$10.5M
$4.5M
-60%
-10%
2021
$23.3M
$17.8M
$8.4M
-6%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $182.8M sold by insiders over 180 days, 517 funds added last quarter, $110.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
CSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSXBLLN

NTRA financials

Revenue growth
+35.9%
XBRL, annual
Net margin
-9.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.7B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-7.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$84.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.20x
long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.63x
TTM operating cash flow over long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30
Return on equity
-12.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-8.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-16.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$58.1B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30, minus cash 2022-12-31
FCF yield
+0.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.3B$1.7B$1.1B$820.2M
Operating income-$309.9M-$222.3M-$446.2M-$541.0M
Net income-$208.2M-$190.4M-$434.8M-$547.8M
EPS (diluted)-1.52-1.53-3.78-5.57
Operating cash flow$215.3M$135.7M-$247.0M-$431.5M
Cashn/an/an/a$466.0M
Long-term debtn/an/a$282.9M$281.7M
SEC XBRL, fiscal years, as known on 2026-10-27

NTRA Stock Sonar score 6/7 axes

Find similar shapesCompare

NTRA ranks highest on growth (84th percentile) and institutional and government (83rd), and lowest on insider conviction (6th), among Healthcare Services peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
35
Inputs
  • Return on equity-12.5% · 39 pct, sector of 70
  • Return on assets-8.7% · 38 pct, sector of 88
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-16.7% · 27 pct, sector of 68
Financial health
70
Inputs
  • Debt to equity0.20x · 58 pct, sector of 61
  • Cash flow to debt0.63x · 82 pct, sector of 66
Growth
84
Inputs
  • Revenue growth, YoY+35.9% · 84 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
6
Inputs
  • Net Form 4 buying (codes P and S), 180d-$89.0M · 13 pct, sector of 64
  • Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
83
Inputs
  • Funds adding, latest quarter517 · 97 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$872K · 68 pct, universe of 1,063
Risk and compliance
53
Inputs
  • Short interest, % of float+4.5% · 53 pct, sector of 95
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NTRA filings, in plain words

Are Natera insiders buying or selling NTRA?

In the 180 days to 2026-10-27, Natera insiders were net sellers, a net $182.8M across purchases and sales reported on Form 4, by 11 sellers.

Have members of Congress traded NTRA?

Yes, but not in the year to 2026-10-27; the latest on record is a purchase by Josh Gottheimer dated 2025-09-22.

Are there planned insider sales of NTRA?

Yes. 23 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $110.4M of stock; the latest, by Sheena Jonathan, was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-27, Natera insiders were net sellers of NTRA, a net $182.8M across purchases and sales reported on Form 4 by 11 sellers. 36% of the 283 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in NTRA, none in the last year; the latest on record is a purchase by Josh Gottheimer dated 2025-09-22. Insiders filed 23 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $110.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies